Pre-Market: ~$112.37 (+2.00%) | Market Cap: ~$4.603 Billion | 52-Week Range: $32.00 - $131.24
Fact: Price sourced from NYSE delayed quote. Yahoo Finance Quote | Nasdaq
Limitation: Real-time prices fluctuate; delayed quotes used here. Volume on July 14: ~525K shares (avg ~659K).
| Period | MANE Return | S&P 500 Return |
|---|---|---|
| YTD (as of Jul 14, 2026) | +233.85% | +10.20% |
| 1-Year | +233.85%* | +20.34% |
| Since IPO (Feb 4, 2026 @ ~$17) | ~+548% (to $110+) | N/A |
*1-year return reflects post-listing performance. Interpretation: Exceptional outperformance likely driven by positive clinical data and sector sentiment around aesthetics/biotech. Uncertainty: Future returns highly speculative due to clinical-stage nature.
Links: Yahoo Historical Data | Seeking Alpha
| Metric | Value | Notes |
|---|---|---|
| Revenue (TTM) | $0 | Pre-commercial clinical stage |
| Net Income (TTM) | -$98.8 Million | Operating losses typical for biotech R&D |
| EPS (TTM) | -$2.64 | Diluted |
| Total Cash (MRQ) | $390.8 Million | Strong post-IPO runway |
| Total Debt/Equity | 0.00% | Debt-free |
| Price/Book (MRQ) | 11.78 | Premium valuation |
| Employees | 24 | As of latest filing |
Interpretation: Robust cash position provides runway into 2027+ for Phase 3 trials and potential commercialization. Uncertainty: No revenue until FDA approval (if achieved); high burn rate expected to continue.
Limitation/Assumption: Financials from Yahoo Finance as of mid-July 2026; exact quarterly details subject to latest 10-Q (next earnings est. Aug 13, 2026). No dividends.
Links: Yahoo Financials | Balance Sheet | Company Website
Fact: Veradermics, Incorporated is a dermatologist-founded, late clinical-stage biopharmaceutical company (incorporated October 2019 in Texas; converted to Delaware 2021; HQ New Haven, CT) developing novel therapeutics for pattern hair loss (androgenetic alopecia/PHL) and other dermatologic/aesthetic conditions. Pipeline includes VDPHL01 (oral extended-release minoxidil, non-hormonal for men/women), plus candidates for warts (VDMN), alopecia areata (VDAA), and molluscum contagiosum (VDMC).
History Fact: IPO on February 4, 2026 (NYSE: MANE), upsized to raise $256.3 million at $17/share (implied ~$596M valuation). Shares opened at $37.75. Recent positive Phase 2/3 data for VDPHL01 in pattern hair loss.
Limitation: Pipeline success depends on ongoing trials; no approved products yet.
Consensus: Strong Buy (100% Buy from 6+ analysts) | Average Price Target: $141.60 (Implied upside ~28.5% from $110.17) | High: $182 | Low: $120
| Analyst/Firm | Date | Rating | Price Target | Action |
|---|---|---|---|---|
| B. Riley Securities | Jul 15, 2026 | Buy | $170 | Initiated |
| Jefferies | Jul 7, 2026 | Buy | $182 (raised from $138) | Maintained/Raised |
| Citi | Jun 22, 2026 | Buy | -- | Initiated |
| LifeSci Capital / Needham | Jun 2026 | Buy | $136-$147 range | Initiated |
Interpretation: High conviction on VDPHL01 potential as first new oral PHL therapy in decades. Uncertainty: Analyst targets can change rapidly with trial data or market conditions; historical accuracy varies.
Limitation: Ratings from limited number of firms; not all analysts covered. Data aggregated from TipRanks/Yahoo/Benzinga reports.
Links: Yahoo Analysts | MarketBeat Forecast | Benzinga Ratings
Interpretation: Indirect B2B2C model via prescribing physicians; large addressable market (~80M US PHL patients). Uncertainty: Actual adoption depends on pricing, insurance coverage, and real-world efficacy/safety post-approval.
| Competitor | Focus | Stage/Status | Notes |
|---|---|---|---|
| Cosmo Pharmaceuticals (Breezula / clascoterone) | Topical anti-androgen for PHL | Clinical (various phases) | Hormonal mechanism; potential competitor in topical space |
| Kintor Pharmaceutical (KX-826) | Topical AR antagonist for PHL | Clinical trials | Asian-focused development; direct PHL rival |
| Pelage Pharmaceuticals (PP405) | Small molecule for hair follicle regeneration | Clinical | Novel mechanism; aesthetics focus |
| Other Biotechs (e.g., Aprea, ProMIS - broader peers) | Various derm/oncology | Clinical-stage | Market cap comparables in biotech space |
Interpretation: VDPHL01 positioned as potential first oral non-hormonal option in ~30 years. Uncertainty: Competitive landscape dynamic; success hinges on superior efficacy, safety, and convenience vs. existing options (e.g., minoxidil topical, finasteride).
Limitation: Competitor data from secondary sources (e.g., analyst notes); full pipeline details require proprietary research. No direct public financial comparison table available.
Links: Company Pipeline | Yahoo Profile
News aggregated; full articles may require subscriptions. Always verify primary sources.